Patients with disorders of sex development

Markosyan, Renata

doi:10.6065/apem.2040240.120

Cited by 6 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In pediatric cases, androgen excess is the commonly observed presentation, followed by Cushing syndrome or a combination of both [4]. Therefore, it is important to consider multiple possibilities in the differential diagnosis of virilization, including androgen-secreting tumors and congenital adrenal hyperplasia [6,7]. Cushing syndrome tends to be more prevalent in older age groups [4].…”

Section: Adrenocortical Tumorsmentioning

confidence: 99%

Overview of endocrine tumor syndromes manifesting as adrenal tumors

Kim

2024

Ewha Med J

View full text Add to dashboard Cite

Endocrine tumor syndromes constitute a group of disorders characterized by tumors in hormoneproducing tissues. These conditions predominantly affect younger patients and often have a familial inheritance. Advances in molecular genetics in recent decades have facilitated the identification of several genes associated with these tumors. The recent World Health Organization classification of adrenocortical tumors integrates the latest developments in pathology, oncology, and molecular biology. In addition, this updated classification includes adrenal cortical diseases based on an understanding of germline susceptibility to these conditions and their clonal-neoplastic nature. Catecholamine-secreting tumors, including pheochromocytoma and paraganglioma, have been found to have a genetic predisposition in as many as 80% of cases. Compared to sporadic cases, endocrine tumor syndromes are more likely to present bilaterally and show synchronous or metachronous disease. This highlights the critical need for early diagnosis, intervention, and ongoing surveillance. This review focuses on the clinical manifestations and genetic basis of endocrine tumor syndromes originating from the adrenal glands.

show abstract

Section: Adrenocortical Tumorsmentioning

confidence: 99%

Overview of endocrine tumor syndromes manifesting as adrenal tumors

Kim

2024

Ewha Med J

View full text Add to dashboard Cite

show abstract

“…Biomedical research has shown the existence of a variety of groups showing variation in bodily form or genetic makeup: XY females, and babies with ambiguous genitals-indeed a range of intersex conditions, some of which may not be identified before adolescence. 25 Undoubtedly, the biological capacity to be a father is often understood to signify masculinity, but it is in fact far from universal.…”

Section: Problems With Applying the Cur-rent Definitions To Men's Hea...mentioning

confidence: 99%

Defining “Men’s Health”

White

Connell

Baker

2023

International Journal of Men's Social and Community Health

View full text Add to dashboard Cite

A definition is required for men’s health that captures current thinking around men and their health and well-being globally. A new definition of men’s health should reflect greater complexity than that has existed in previously accepted, over-simplistic definitions of what constitutes “men’s health.” In addition, the most com-monly used definitions in the field that originated from the westernised countries of the Global North do not seem to be inclusive of the heterogeneity among a significant proportion of the world’s population. Definitions are important as they help drive academic endeavour, practice and policy; they also help shape organisations working in men’s health and, as such, they need to be as broad as possible. This paper outlines the limitationsand conceptual concerns in the current definitions and argues for a more inclusive definition.

show abstract

“…3) CHH is one of the few treatable diseases of male infertility, although men with primary testicular dysfunction show irreversibly diminished spermatogenic capacity. [4][5][6] The approach to CHH treatment is determined by goals such as developing only virilization or inducing fertility. In this review, we describe therapeutic options from different perspectives.…”

Section: Introductionmentioning

confidence: 99%

Treatment of congenital hypogonadotropic hypogonadism in male patients

Lee

Shim

Hwang

2022

Ann Pediatr Endocrinol Metab

View full text Add to dashboard Cite

Congenital hypogonadotropic hypogonadism (CHH) is characterized by complete or partial failure of pubertal development because of inadequate secretion of gonadotropic hormones. CHH consists of hypogonadotropic hypogonadism with anosmia or hyposmia, Kallmann syndrome, and the normosmic variation normosmic idiopathic hypogonadotropic hypogonadism. CHH is one of the few treatable diseases of male infertility, although men with primary testicular dysfunction have irreversibly diminished spermatogenic capacity. The approach to CHH treatment is determined by goals such as developing virilization or inducing fertility. This review focuses on the current knowledge of therapeutic modalities for inducing puberty and fertility in men with CHH.

show abstract

Patients with disorders of sex development

Cited by 6 publications

References 24 publications

Overview of endocrine tumor syndromes manifesting as adrenal tumors

Overview of endocrine tumor syndromes manifesting as adrenal tumors

Defining “Men’s Health”

Treatment of congenital hypogonadotropic hypogonadism in male patients

Contact Info

Product

Resources

About